Axiom Investors LLC DE Has $3.83 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Axiom Investors LLC DE decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 4.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,904 shares of the biotechnology company’s stock after selling 1,920 shares during the period. Axiom Investors LLC DE owned 0.07% of Blueprint Medicines worth $3,829,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines by 22.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after purchasing an additional 729,055 shares during the last quarter. Norges Bank bought a new position in Blueprint Medicines in the fourth quarter valued at approximately $62,028,000. State Street Corp boosted its stake in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock valued at $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Jennison Associates LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth $31,417,000. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Blueprint Medicines by 161.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after acquiring an additional 306,079 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of BPMC opened at $88.51 on Tuesday. The company has a 50 day moving average of $97.70 and a 200-day moving average of $94.07. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $5.66 billion, a P/E ratio of -81.95 and a beta of 0.58. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,608 shares of company stock valued at $3,319,587. 4.21% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BPMC shares. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Piper Sandler boosted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Wedbush reiterated an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research report on Friday, February 28th. Scotiabank assumed coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They issued a “buy” rating and a $135.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.